FDA has informed generics and active pharmaceutical ingredient (API) manufacturers that they will have one month to self-identify for the generics drug user fees for fiscal year (FY) 2014.
Generics makers to self-identify for FY2014 generics fees
Home/Policies & Legislation
|
Posted 10/05/2013
0
Post your comment
The agency announced on 16 April 2013 that generics drug facilities will be required to self-identify during the period from 1 May 2013 to 1 June 2013, so that FDA can calculate the user fees to be paid for FY 2014.
Legislation to allow FDA to collect user fees from industry was passed by US Congress in September 2012 [1]. Generics drug facilities, certain sites and organizations identified in a generic drug submission are required by the Generic Drug User Fee Amendments of 2012 (GDUFA) to submit, update or reconfirm identification information to FDA annually.
The agency collected its first user fees as part of the GDUFA for FY 2013. These were higher than expected due to the relatively low number of facilities self-identifying (1,643). This led to fees for domestic finished drug formulation facilities of US$175,389 and API facilities of US$26,458, while non-US facilities paid US$15,000 more than domestic facilities to cover the extra costs of inspecting foreign facilities [2].
As part of the president’s FY 2014 budget, FDA is requesting a budget of US$4.7 billion to protect and promote the public health. Industry user fees would fund 94% of the proposed budget increase.
The generics user fees for FY 2014 are due to be paid on the first business day on or after 1 October 2013 and FDA expects to publish the GDUFA fee rates 60 days before the start of the fiscal year. The FY 2014 covers the period from 1 October 2013 through 30 September 2014.
Related article
Twenty per cent of generic drug user fees to come from API manufacturers
References
1. GaBI Online - Generics and Biosimilars Initiative. Generic drug user fees come into effect [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 May 10]. Available from: www.gabionline.net/Policies-Legislation/Generic-drug-user-fees-come-into-effect
2. GaBI Online - Generics and Biosimilars Initiative. FDA gives details of generic drug user fees [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 May 10]. Available from: www.gabionline.net/Policies-Legislation/FDA-gives-details-of-generic-drug-user-fees
Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Source: FDA
Guidelines
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
Reports
Central America moves toward joint evaluation of biosimilar medicines
The US$52 billion question: can the US keep biosimilars competitive?
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
ANVISA updates understanding on biosimilar interchangeability
China's 12th VBP round accelerates shift to generics and biosimilars dual-track
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Home/Policies & Legislation Posted 15/09/2026
Congress pushes biosimilar bills as interchangeability concerns linger
Home/Policies & Legislation Posted 02/09/2026
ANVISA updates understanding on biosimilar interchangeability
Home/Policies & Legislation Posted 22/07/2026
China's 12th VBP round accelerates shift to generics and biosimilars dual-track
Home/Policies & Legislation Posted 03/07/2026
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment